CADTH has received the following notice(s) of pending drug submission(s).
|Manufacturer||Novartis Pharmaceuticals Canada Inc.||Novartis Pharmaceuticals Canada Inc.|
|Indication(s)||For the treatment of patient with secondary progressive multiple sclerosis.||Macular degeneration, age-related|
|Call for patient input||2019-08-28||2019-08-28|
|Patient input deadline||2019-10-18||2019-10-18|
|Submit patient input||Submit||Submit|
|Register as Clinical Expert||Register||Register|
- If you are interested in contributing, more information can be found at CADTH Common Drug Review Patient Input and when you are ready to provide input, click on ‘Submit”.
- If you are interested in participating as a clinical expert, more information can be found at Clinical Expert involvement in CADTH’s Common Drug Review and Optimal Use of Drugs. If you are interested in participation, please click on “Register”.